Increased copy number of 23S ribosomal RNA gene with point mutation in MRSA associated with linezolid resistance in a patient treated with long-term linezolid.
Humans
Linezolid
/ pharmacology
Methicillin-Resistant Staphylococcus aureus
Genes, rRNA
RNA, Ribosomal, 23S
/ genetics
Point Mutation
Anti-Bacterial Agents
/ pharmacology
DNA Copy Number Variations
Staphylococcal Infections
/ drug therapy
Drug Resistance, Bacterial
/ genetics
Microbial Sensitivity Tests
23S ribosomal RNA gene
G2576T
Linezolid resistance
Long-term
Methicillin-resistant Staphylococcus aureus
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
06
12
2022
revised:
19
01
2023
accepted:
25
01
2023
medline:
4
4
2023
pubmed:
4
2
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Methicillin-resistant Staphylococcus aureus (MRSA) infection is one of the most difficult infections we have to treat. Linezolid is one of the effective treatment options for refractory MRSA infections. There are cases where we are forced to use long-term linezolid treatment for refractory MRSA infections. To discuss the evolution of Linezolid resistance factors in clinical isolates of MRSA. We investigated 16 MRSA isolated from a patient treated with linezolid for a long period of 75 days. We performed antibiotic susceptibility test, 23S rRNA genes sequencing analysis, Pulsed-field gel electrophoresis. MRSA isolates were susceptible to linezolid before the start of treatment, but became less susceptible by prolonged treatment. The 23S rRNA sequencing analysis of linezolid-resistant strains that appeared 17 days after the start of treatment with linezolid revealed that all resistant MRSA had the G2576T substitution (Escherichia coli 23S rRNA gene number). The number of copies of this mutation increased with the use of linezolid. Long-term use of linezolid in a patient or reuse of linezolid in a patient who has been previously treated with linezolid can lead to the emerging of linezolid-resistant MRSA in the host.
Sections du résumé
BACKGROUND
BACKGROUND
Methicillin-resistant Staphylococcus aureus (MRSA) infection is one of the most difficult infections we have to treat. Linezolid is one of the effective treatment options for refractory MRSA infections. There are cases where we are forced to use long-term linezolid treatment for refractory MRSA infections.
OBJECTIVE
OBJECTIVE
To discuss the evolution of Linezolid resistance factors in clinical isolates of MRSA.
METHODS
METHODS
We investigated 16 MRSA isolated from a patient treated with linezolid for a long period of 75 days. We performed antibiotic susceptibility test, 23S rRNA genes sequencing analysis, Pulsed-field gel electrophoresis.
RESULTS
RESULTS
MRSA isolates were susceptible to linezolid before the start of treatment, but became less susceptible by prolonged treatment. The 23S rRNA sequencing analysis of linezolid-resistant strains that appeared 17 days after the start of treatment with linezolid revealed that all resistant MRSA had the G2576T substitution (Escherichia coli 23S rRNA gene number). The number of copies of this mutation increased with the use of linezolid.
CONCLUSION
CONCLUSIONS
Long-term use of linezolid in a patient or reuse of linezolid in a patient who has been previously treated with linezolid can lead to the emerging of linezolid-resistant MRSA in the host.
Identifiants
pubmed: 36736701
pii: S1341-321X(23)00031-4
doi: 10.1016/j.jiac.2023.01.019
pii:
doi:
Substances chimiques
Linezolid
ISQ9I6J12J
RNA, Ribosomal, 23S
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-484Informations de copyright
Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declare no conflict of interest.